Advancing Brain Targeting: Cost-Effective Surface-Modified Nanoparticles for Faster Market Entry
Open Access
- 17 May 2025
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (5) , 661
Abstract
Background/Objectives: The blood–brain barrier (BBB) poses a major obstacle to delivering therapeutic agents to the central nervous system (CNS), driving the need for innovative drug delivery strategies. Among these, nanoparticles (NPs) have gained attention due to their ability to enhance drug transport, improve bioavailability, and enable targeted delivery. Methods: This paper explores various surface modification strategies employed to optimize NP-mediated drug delivery across the BBB. Specifically, the functionalization of NPs with ligands such as transferrin (Tf), lactoferrin (Lf), protamine, and insulin is discussed, each demonstrating unique mechanisms for enhancing brain-targeting efficiency. In addition, this work provides a comprehensive overview of recent scientific advancements and market strategies aimed at accelerating the adoption of low-cost, surface-modified nanoparticles, ultimately improving patient access to effective CNS treatments. Conclusions: Preclinical and in vitro studies have demonstrated the effectiveness of these modifications in increasing drug retention and bioavailability in brain tissues. Additionally, while ligand-conjugated NPs hold significant promise for neuropharmacology, their clinical translation is often hindered by regulatory and economic constraints. Lengthy approval processes can slow market entry, but cost–benefit analyses indicate that surface-modified NPs remain financially viable, particularly as scalable manufacturing techniques and some ligands are cost-efficient.Keywords
Funding Information
- FCT/MCTES (PIDDAC) (UIDB/00511/2020, UIDP/00511/2020, LA/P/0045/2020, CEEC-IND/01741/2021, M-ERA-NET3/0001/2021, 10.54499/M-ERA-NET3/0001/2021, 958174)
- ALICE (UIDB/00511/2020, UIDP/00511/2020, LA/P/0045/2020, CEEC-IND/01741/2021, M-ERA-NET3/0001/2021, 10.54499/M-ERA-NET3/0001/2021, 958174)
- Scientific Employment Stimulus - Individual Call (UIDB/00511/2020, UIDP/00511/2020, LA/P/0045/2020, CEEC-IND/01741/2021, M-ERA-NET3/0001/2021, 10.54499/M-ERA-NET3/0001/2021, 958174)
- M-ERA-NET3 network “ERA-NET for research and innovation in materials and battery technologies” (UIDB/00511/2020, UIDP/00511/2020, LA/P/0045/2020, CEEC-IND/01741/2021, M-ERA-NET3/0001/2021, 10.54499/M-ERA-NET3/0001/2021, 958174)
- Foundation for Science and Technology (UIDB/00511/2020, UIDP/00511/2020, LA/P/0045/2020, CEEC-IND/01741/2021, M-ERA-NET3/0001/2021, 10.54499/M-ERA-NET3/0001/2021, 958174)
- Project Nano4Glio that was selected in the Joint Transnational Cofund Call 2021 of M-ERA.NET 3 (UIDB/00511/2020, UIDP/00511/2020, LA/P/0045/2020, CEEC-IND/01741/2021, M-ERA-NET3/0001/2021, 10.54499/M-ERA-NET3/0001/2021, 958174)
This publication has 136 references indexed in Scilit:
- Nanoparticles With Surface Antibody Against CD98 and Carrying CD98 Small Interfering RNA Reduce Colitis in MiceGastroenterology, 2014
- Glioma targeting and blood–brain barrier penetration by dual-targeting doxorubincin liposomesBiomaterials, 2013
- Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrierBiomaterials, 2013
- Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging CapabilitiesScience, 2012
- Enzyme-responsive nanoparticles for drug release and diagnosticsAdvanced Drug Delivery Reviews, 2012
- PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug DeliveryCurrent Drug Metabolism, 2012
- Gadolinium-loaded polymeric nanoparticles modified with Anti-VEGF as multifunctional MRI contrast agents for the diagnosis of liver cancerBiomaterials, 2011
- Targeting the insulin receptor: nanoparticles for drug delivery across the blood–brain barrier (BBB)Journal of Drug Targeting, 2010
- Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimagingParticle and Fibre Toxicology, 2010
- Engineering design and molecular dynamics of mucoadhesive drug delivery systems as targeting agentsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009